Please try another search
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Huiping Lu | 55 | - | Executive Deputy GM & Director |
Zelin Sheng | 62 | - | Chairman of the Board & GM |
Jisheng Wu | 57 | - | Director & Deputy GM |
Binhua Lv | 45 | 2019 | Deputy General Manager & Director |
Ruyi He | 62 | - | Independent Director |
Junchao Zhang | 43 | 2022 | Supervisor |
Binghui Zhang | 59 | - | Independent Director |
Fanzhi Huang | 56 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review